PDGFRA and neoplasm: KIT mutations (vs PDGFRA mutations and wild-type) associated with increased risk for tumor size >5 cm, higher mitotic activity, recurrence, and metastasis. KIT mutations: recurrence RR = 2.06 (95% CI: 1.37–3.11; P = 0.0005); metastasis RR = 2.77 (95% CI: 1.64–4.67; P = 0.0001)